| Literature DB >> 33765616 |
Abstract
The Src Family Kinases (SFKs) are pivotal regulators of cellular signal transduction and highly sought-after targets in drug discovery. Their actions within cells are controlled by alterations in protein phosphorylation that switch the SFKs from autoinhibited to active states. The SFKs are also well recognized to contain redox-active cysteine residues where oxidation of certain residues directly contribute to kinase function. To more completely understand the factors that influence cysteine oxidation within the SFKs, a review is presented of the local structural environments surrounding SFK cysteine residues compared to their quantified oxidation in vivo from the Oximouse database. Generally, cysteine local structure and degree of redox sensitivity vary with respect to sequence conservation. Cysteine residues found in conserved positions are more mildly redox-active as they are found in hydrophobic environments and not fully exposed to solvent. Non-conserved redox-active cysteines are generally the most reactive with direct solvent access and/or in hydrophilic environments. Results from this analysis motivate future efforts to conduct comprehensive proteome-wide analysis of redox-sensitivity, conservation, and local structural environments of proteins containing reactive cysteine residues.Entities:
Keywords: Cysteine; Protein biochemistry; Redox signaling; Signal transduction; Structural biology; Thiol oxidation; Tyrosine kinase
Year: 2021 PMID: 33765616 PMCID: PMC8022254 DOI: 10.1016/j.redox.2021.101934
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1Structural basis for activation of the non-receptor Src family kinases from X-ray crystallography. A) The sequence of all SFKs contain a “Src module” consisting of consecutive encoding of structured SH3, SH2, and a kinase domains following a unique sequence in each SFK. Generally, two regulatory tyrosines (Y416 and Y527 in the chicken Src sequence numbers) serve as targets of phosphorylation & dephosphorylation. B) The Autoinhibited (closed) structure of Src (PDB code 2SRC) contains the Src module folded into a compact structure with SH2 an SH3 domains maintaining the kinase domain in the inactive conformation dependent on dephosphorylation at Y416 and phosphorylation at 527. C) Activation of Src is multifaceted and can proceed via any combination of engagement of SH2 with phosphopeptides, competition of the SH2-kinase linker with exogenous polyproline peptide motifs (-XPpXP-), and dephosphorylation at pY527. D) Structure of the active kinase domain containing unfolded, phosphorylated A-loop (pY416) and inward rotated αC-helix (PDB ID 3DQW). E) View of catalytic cleft of autoinhibited versus (PDB ID 2SRC)) and F) active Src (PDB ID 3DQW) showing the structural consequences of A-loop unfolding and the formation of the Lys-295 to Glu-310 H-bond via inward rotation of the αC-helix.
Fig. 2Structure of the SH2 Domain and CysteineStructuralEnvironments. A) Overall fold of the Src SH2 domain (orange) in complex with pTyr-527 C-terminal peptide (purple) from PDB ID 2SRC. Local structural environment for B) Cys-185, C) Cys-222 (visualized from LYN structure, PDB ID 4TZI), D) Cys-238, and E) Cys-245. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3Sequence homology of cysteine residues of SFK SH2 domains and percent oxidation. A) Secondary structural elements of SFK SH2 domains and location of cysteine residues. B) Sequence homology of residues at positions of cysteine residues. Two residues are specified if there is a difference between human and mouse sequences. The right and left most residues correspond to human and mouse, respectively. C) Visualization of percent oxidation from Oximouse. Abbreviations (BAT, brown adipose tissue; epi, epididymal fat; sub Q, subcutaneous fat; skm, skeletal muscle; N.D., not detected).
SFK SH2 domain cysteine residue sequence numbers and corresponding positions in chicken Src.
| Src | Chicken | Cys-185 | Lys-206 | Ser-222 | Cys-238 | His-239 | Cys-245 |
| Human | Cys-188 | Lys-209 | Ser-225 | Cys-241 | His-242 | Cys-248 | |
| Mouse | Cys-193 | Lys-214 | Ser-230 | Cys-246 | His-247 | Cys-253 | |
| YES1 | |||||||
| Human | Ser-195 | Lys-216 | Thr-232 | Cys-248 | His-249 | Cys-255 | |
| Mouse | Ser-193 | Lys-214 | Thr-230 | Cys-246 | His-249 | Cys-253 | |
| FYN | |||||||
| Human | Ser-186 | Lys-207 | Thr-223 | Cys-239 | Cys-240 | Cys-246 | |
| Mouse | Ser-186 | Lys-207 | Thr-223 | Cys-239 | Cys-240 | Cys-246 | |
| FGR | |||||||
| Human | Ser-181 | Lys-202 | Ser-218 | Cys-234 | Asn-245 | Cys-240 | |
| Mouse | Ser-169 | Lys-190 | Ser-206 | Cys-222 | Asn-223 | Cys-228 | |
| BLK | |||||||
| Human | Ser-161 | Cys-181 | Ser-197 | Cys-213 | Gln-214 | Cys-220 | |
| Mouse | Ser-167 | Ser-175 | Thr-203 | Cys-219 | Gln-222 | Cys-226 | |
| LYN | |||||||
| Human | Ser-166 | Ser-187 | Cys-203 | Cys-219 | Arg-220 | Cys-226 | |
| Mouse | Ser-166 | Ser-187 | Cys-203 | Cys-219 | Arg-220 | Cys-226 | |
| HCK | |||||||
| Human | Ser-181 | Thr-202 | Thr-218 | Cys-234 | Gln-235 | Cys-241 | |
| Mouse | Ser-179 | Thr-200 | Ser-216 | Cys-232 | Gln-233 | Cys-239 | |
| LCK | |||||||
| Human | Ser-164 | Asn-185 | Gly-201 | Cys-217 | Thr-218 | Cys-234 | |
| Mouse | Ser-164 | Asn-185 | Gly-201 | Cys-217 | Thr-218 | Cys-234 | |
SFK kinase domain cysteine residue sequence numbers and corresponding positions in chicken Src.
| Src | Chicken | Cys-277 | Ser-342 | Ser-345 | Val-399 | Cys-400 | Arg-419 | Arg-438 | Cys-483 | Cys-487 | Cys-496 | Cys-498 |
| Human | Cys-280 | Ser-345 | Ser-348 | Val-402 | Cys-403 | Arg-422 | Arg-442 | Cys-486 | Cys-490 | Cys-499 | Cys-501 | |
| Mouse | Cys-285 | Asn-350 | Ser-353 | Val-407 | Cys-408 | Arg-427 | Arg-447 | Cys-491 | Cys-495 | Cys-504 | Cys-506 | |
| YES1 | Human | Cys-287 | Ser-352 | Ser-355 | Val-409 | Cys-410 | Arg-427 | Arg-446 | Cys-493 | Cys-497 | Asn-506 | Cys-508 |
| Mouse | Cys-285 | Ser-350 | Ser-353 | Ile-407 | Cys-408 | Arg-425 | Arg-444 | Cys-491 | Cys-495 | Asn-504 | Cys-506 | |
| FYN | Human | Gln-281 | Asn-346 | Ser-349 | Ile-403 | Cys-404 | Arg-423 | Arg-442 | Cys-487 | Cys-491 | Ile-500 | Cys-502 |
| Mouse | Gln-281 | Ser-346 | Ser-349 | Ile-403 | Cys-404 | Arg-423 | Arg-442 | Cys-487 | Cys-491 | Ile-500 | Cys-502 | |
| FGR | Human | Cys-273 | Cys-338 | Ser-341 | Ala-395 | Cys-396 | Cys-415 | Arg-434 | Cys-479 | Cys-483 | Glu-492 | Thr-494 |
| Mouse | Cys-261 | Cys-326 | Ser-329 | Ile-383 | Cys-384 | Gln-403 | Arg-422 | Cys-467 | Cys-471 | Glu-480 | Ala-482 | |
| BLK | Human | Gln-251 | Ala-316 | Cys-319 | Cys-373 | Cys-374 | Gln-393 | Val-411 | Arg-456 | Cys-460 | Ala-470 | Cys-472 |
| Mouse | Gln-245 | Ala-310 | Cys-313 | Cys-367 | Cys-368 | Gln-386 | Val-405 | Cys-450 | Cys-454 | Thr-464 | Cys-466 | |
| LYN | Human | Gln-257 | Ala-323 | Ser-326 | Met-380 | Cys-381 | Arg-400 | Cys-419 | Arg-464 | Cys-468 | Lys-477 | Cys-479 |
| Mouse | Gln-257 | Ala-323 | Ser-326 | Met-380 | Cys-381 | Arg-400 | Cys-419 | Arg-464 | Cys-468 | Lys-477 | Cys-479 | |
| HCK | Human | Gln-272 | Ala-337 | Ser-340 | Val-394 | Cys-395 | Arg-414 | Ser-433 | Arg-478 | Cys-482 | Met-491 | Cys-493 |
| Mouse | Gln-270 | Ala-335 | Ser-338 | Val-392 | Cys-393 | Arg-412 | Ser-431 | Arg-476 | Cys-480 | Ile-489 | Cys-491 | |
| LCK | Human | Gln-255 | Glu-320 | Ser-323 | Ser-377 | Cys-378 | Arg-397 | Thr-416 | Arg-461 | Cys-465 | Arg-474 | Cys-476 |
| Mouse | Gln-255 | Glu-320 | Ser-323 | Ser-377 | Cys-378 | Arg-397 | Thr-416 | Arg-461 | Cys-465 | Met-474 | Cys-476 | |
Fig. 4Structure of the Src Kinase Domain and CysteineStructuralEnvironments. A) Overall fold of the Src kinase domain (light blue), ɑC-helix (red), A-loop (orange) in complex with AMP-PNP defining the ATP-binding site from PDB ID 2SRC. Local structural environment for B) Cys-277, Cys-342, and Cys-345 near the ATP binding site and folded A-loop. C) Local hydrophobic residues around Cys-400. D) Placement of Cys-438 near hydrophilic residues, Tyr-416, and Glu-415 of the A-loop in the active kinase (PDB ID 1Y57). E) and F) Organization of the Cys-483, Cys-487, Cys-496, and Cys-498 cluster located near the C-terminal ɑH-helix. In cases where Cys residues are not present in the 2SRC kinase domain, the corresponding position has been mutated to a cysteine in PyMol. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 5Sequence homology of cysteine residues of SFK kinase domains and percent oxidation. A) Secondary structural elements of SFK kinase domains and location of cysteine residues (colors consistent with Fig. 4). B) Sequence homology of residues at positions of cysteine residues. Two residues are specified if there is a difference between human and mouse sequences. The right and left most residues corresponds to human and mouse, respectively. C) Visualization of percent oxidation from Oximouse. Abbreviations (BAT, brown adipose tissue; epi, epididymal fat; subQ, subcutaneous fat; skm, skeletal muscle; N.D., not detected). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Modifications and functional outcomes of SFK cysteine oxidation and detected oxidation in young and old mice from oximouse.
| Cysteine Residue1 | Modification (Functional Outcome) | Tissue Location of Oxidized Cysteine in Oximouse [ | ||
|---|---|---|---|---|
| Young Mice | Old Mice | |||
| Src | Cys-185 | Disulfide (Cortactin Binding) [ | Brain, Epi, Kidney, subQ | Brain, Epi, Lung, subQ |
| Sulfenic Acid (Activating) [ | ||||
| Cys-238 | NR | Brain, Lung | Brain, Lung | |
| Cys-245 | Proposed Disulfide (Activating) [ | Brain, Lung, Spleen | Brain, Lung | |
| ND (Activating) [ | ||||
| Cys-277 | Sulfenic Acid (Activating) [ | Lung | Kidney, Lung | |
| Disulfide (Inactivating) [ | ||||
| Cys-400 | NR | Brain, Epi, Kidney, Lung | Brain, Epi, Kindey, Lung, Spleen | |
| Cys-483 | ND (Activating) [ | Not detected | Not detected | |
| Cys-487 | ND (Activating) [ | Not detected | Not detected | |
| Disulfide (Activating) [ | ||||
| Cys-496 | ND (Activating) [ | Not detected | Not detected | |
| Cys-498 | ND (Activating) [ | Not detected | Not detected | |
| Non-identified | ND (Activating) [ | |||
| Sulfenic Acid (Activating) [ | ||||
| YES1 | Cys-238 | NR | Brain | Not detected |
| Cys-245 | NR | BAT, Epi, Heart, Kidney, Lung | BAT, Brain, Epi, Lung | |
| Cys-277 | NR | Kidney, Liver | Kidney, Liver, Lung, Spleen | |
| Cys-400 | NR | Brain, Liver, Lung, skm | Brain, Epi, Heart, Lung, Spleen | |
| FYN | Cys-245 | NR | Brain, Spleen | Brain, Heart, Kidney, Liver, Spleen |
| Cys-400 | NR | Epi, Lung | Brain, Epi, Lung | |
| Cys-487 | ND (Activating) [ | Not detected | Not detected | |
| Not specified | Sulfenic Acid (Activating) [ | |||
| FGR | Cys-342 | NR | Spleen | Spleen |
| BLK | Cys-345 | NR | Spleen | Spleen |
| LYN | Cys-222 | NR | Brain, Kidney, Lung, Spleen | BAT, Epi, Kidney, Liver, Spleen |
| Cys-400 | NR | BAT, Brain, Kidney, Lung, skm, Spleen | BAT, Epi, Kidney, Lung Spleen | |
| Cys-438 | NR | Brain, Kidney, Liver, Spleen | BAT, Brain, Liver, Spleen | |
| Cys-487 | ND (Activating) [ | BAT, Brain, Lung, Spleen | Bat, Brain, Epi, Kidney, Lung, Spleen | |
| HCK | Cys-238 | NR | Spleen | Not detected |
| Cys-400 | NR | Spleen | Not detected | |
| Cys-487 | NR | Lung, Spleen | Lung, Spleen | |
| Not specified | ND (Activating) [ | |||
| LCK | Cys-400 | NR | Spleen | Spleen |
| Cys-487 & Cys-498 | ND (Activating) [ | Not detected | Not detected | |
Adapted and modified from Table 1 of ref [16]. 1Sequece numbers in this table are from chicken Src for consistency. 2Oximouse tissue abbreviations (BAT, brown adipose tissue; epi, epididymal fat; subQ, subcutaneous fat; skm, skeletal muscle). NR “None Reported” designates a specific cysteine residue where oxidation has not been addressed previously. ND “Not Determined” designates a cysteine where the referenced study does not determine the modification. A graphical representation of the Oximouse percent oxidations along with sequence conservation can be found in Fig. 3, Fig. 5.